New targeted agent produces considerable responses in trial with patients with uterine serous carcinoma
Dana-Farber Cancer InstituteThe DNA repair-blocking drug adavosertib shrinks tumors in nearly one-third of patients in clinical trial. Data will be shared virtually at the Society for Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer.